Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody

Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2
Clone	Spartalizumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	143.14 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4